Lixte Biotechnology Inc. (LIXT)
NASDAQ: LIXT
· Real-Time Price · USD
3.56
-0.34 (-8.72%)
At close: Aug 15, 2025, 3:59 PM
3.62
1.69%
After-hours: Aug 15, 2025, 05:16 PM EDT
Lixte Biotechnology Cash Flow Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Net Income | -775.67K | -709.55K | -617.69K | -986.03K | -1.01M | -971.32K | -1.03M | -1.02M | -1.67M | -1.37M | -1.63M | -1.48M | -1.55M | -1.66M | -2.03M | -1.24M | -1.73M | -1.73M |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Stock-Based Compensation | n/a | 99.74K | 77.98K | n/a | 130.69K | 102.93K | 104.06K | 112.11K | 280.06K | 276.98K | 385.39K | 396.88K | 424.09K | 339.67K | 744.86K | 347.22K | 850.8K | 656.03K |
Other Working Capital | 40.52K | -15.44K | -58.96K | 21.05K | 176.47K | -10.76K | 91.46K | 107.62K | 70.01K | -174.56K | 115.1K | -174.24K | -116.27K | 138.62K | 127.32K | -36.38K | -159.48K | 86.2K |
Other Non-Cash Items | 268K | n/a | n/a | 168.79K | n/a | n/a | n/a | n/a | 137.16K | 283.11K | 463.02K | 462.19K | -113.05 | 196.15K | 734.54K | 294.03K | 837.23K | 697.45K |
Deferred Income Tax | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Change in Working Capital | 20.19K | 41.33K | -58.96K | -140.36K | 61.19K | 79.17K | 26.07K | -37.73K | 212.91K | -180.69K | 37.47K | -92.81K | -72.05K | 282.15K | 137.65K | -36.38K | -159.48K | 44.77K |
Operating Cash Flow | -487.49K | -568.48K | -598.67K | -957.6K | -819.04K | -789.23K | -902.12K | -944.39K | -1.18M | -1.27M | -1.21M | -1.17M | -1.19M | -1.04M | -1.15M | -927.88K | -1.04M | -1.03M |
Capital Expenditures | 5.00 | 3.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cash Acquisitions | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -5.14M | 5.14M | n/a | n/a | n/a | n/a | n/a | n/a |
Purchase of Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | 914.23K | n/a | n/a | n/a | n/a | 3.14M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Investing Cash Flow | n/a | 914.23K | n/a | n/a | n/a | n/a | 3.14M | n/a | n/a | n/a | -5.14M | 5.14M | n/a | n/a | n/a | n/a | n/a | n/a |
Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 41.00 | n/a | 6.28K | 5.14M | 5.14M | 10.91K | -10.91K | 10K | 90K | 101K | 6.63K |
Financial Cash Flow | -10K | 914.23K | n/a | n/a | n/a | n/a | n/a | 3.14M | n/a | 6.28K | 5.14M | 5.14M | 5.15M | -10.91K | 10K | 90K | 101K | 3.7M |
Net Cash Flow | -497.49K | 345.75K | -598.67K | -957.6K | -819.04K | -789.23K | -902.12K | 2.19M | -1.18M | -1.27M | -1.21M | -1.17M | 3.96M | -1.05M | -1.14M | -837.88K | -940.85K | 2.67M |
Free Cash Flow | -487.49K | -568.48K | -598.67K | -957.6K | -819.04K | -789.23K | -902.12K | -944.39K | -1.18M | -1.27M | -1.21M | -1.17M | -1.19M | -1.04M | -1.15M | -927.88K | -1.04M | -1.03M |